Navigation Links
Genprex Announces New Patent Issuance in Japan
Date:10/18/2011

AUSTIN, Texas, Oct. 18, 2011 /PRNewswire/ -- A new patent covering tumor suppression technologies, including the company's lead product candidate Oncoprex™, was recently awarded to The University of Texas System by the Japan Patent Office. Patent number 4813746 pertains to the discovery that chromosome 3p21.3 genes act as cancer suppressors. The family of tumor suppressors include TUSC2, also known as FUS1, the anti-cancer agent in Oncoprex therapy which is undergoing clinical evaluation for lung cancer patients in the U.S.

"Japan represents an important clinical population," stated Chief Operating and Financial Officer Greg Heinlein. "We intend to include Japanese collaborators in our development and commercialization plans and have begun to establish key relations within the region, including appointments of leading oncology experts to our Medical and Scientific Advisory Board."

Genprex controls a portfolio of biomedical technologies including targeted molecular therapeutics for cancer and other diseases. The novel technologies, including those licensed exclusively from The University of Texas MD Anderson Cancer Center, are protected by 15 issued patents and 9 pending applications in major market areas. These broadly applicable technologies have been the subject of more than 20 peer-reviewed scientific publications in the fields of cancer, genomics and molecular biology.

About Oncoprex™Oncoprex is a nanomolecular therapy harnessing the TUSC2 tumor suppressor. TUSC2 defects are associated with most major cancers and >85% of lung cancers. Intravenous Oncoprex induces apoptosis or programmed cell death in cancer cells and controls cell signaling and inflammation to fight cancer along universal cancer pathways. In phase I clinical testing of Stage IV lung cancer patients, Oncoprex monotherapy was well tolerated and demonstrated clinically significant anti-cancer activity in primary lung tumors and metastatic tumors, including liver and pancreas. A phase II clinical trial evaluating Oncoprex in combination with Tarceva® (erlotinib) is planned for 2012. The trial will enroll lung cancer patients without the EGFR mutation and patients with EGFR mutations who have become unresponsive to erlotinib.

About GenprexGenprex, Inc. is a privately held, clinical-stage biopharmaceutical company developing nanomolecular therapies that control universal cancer pathways to unlock the unrealized potential of a variety of targeted cancer therapies. For more information about Genprex click here. Tarceva® is a registered trademark of the Roche Group, including Genentech and Chugai, and of Astellas Pharma.Contact:

Greg HeinleinPhone:

512-597-5900www.genprex.com
'/>"/>

SOURCE Genprex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. SomaLogic Announces Research Agreement with Leading Global Pharmaceutical Company to Accelerate Pharmaceutical Discovery and Development
2. Rock Creek Pharmaceuticals Announces Expanded International Shipping Options for Anatabloc™, Physician Conferences on Anatabine Research
3. Hologic Announces Jury Verdict in Patent Infringement Suit
4. Regeneron Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes due October 1, 2016
5. Aethlon Medical Announces Availability of its Exosome Detection Assay to the Research Community
6. Hospira Announces Certain Preliminary Third-Quarter 2011 Results
7. Ampio Pharmaceuticals Announces a Proof of Concept Trial of Danazol in the Treatment of Allergic Rhinitis Supports Mechanism of Action of Optina™
8. Bend Research Announces Schedule of Events at 2011 AAPS Annual Meeting and Exposition
9. Pacira Pharmaceuticals, Inc. Announces Key EXPAREL™ Data to be Presented at American College of Surgeons 97th Annual Clinical Congress
10. Halozyme Announces Positive Results from Roches Subcutaneous Herceptin Phase 3 Trial
11. Express Scripts Announces Third Quarter 2011 Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... 21, 2017 Mass Spectrometer Market: Overview ... This report on mass spectrometer ... prospects of the market globally. The stakeholders of ... the manufacture and commercialization of various mass spectrometer ... planning to enter this market. This report comprises ...
(Date:2/21/2017)... -- Luminex Corporation (NASDAQ: LMNX ) (the "Company") today ... of a quarterly cash dividend to its shareholders, the first ... payable on April 14, 2017 to shareholders of record as ... The board of directors intends for the Company ... holders of its common stock, representing a planned annual dividend ...
(Date:2/21/2017)... Feb. 21, 2017  Global health services company Cigna ... ® for breast reconstruction surgery and Dermacell ... an advanced acellular dermal matrix developed by LifeNet Health ... NVDQ ) "We are proud ... health-care payers to review the growing base of evidentiary ...
Breaking Medicine Technology:
(Date:2/21/2017)... ... ... As recently as 2015, rhinoplasty was one of the Top 5 cosmetic ... patients want to make a change in the appearance of their nose while others ... team at usrhinoplasty.org is expanding its article database to better inform its ...
(Date:2/21/2017)... ... 2017 , ... American Veterinarian™, the premier multimedia provider of ... first bi-monthly issue of 2017 in February. The inaugural issue will offer expert ... , In making the announcement, American Veterinarian™ Publisher Chris Hennessy said, “We ...
(Date:2/21/2017)... San Francisco, California (PRWEB) , ... February 21, ... ... in the world with over 50,000 participants. The connected care demonstration spanned ... Office of the National Coordinator, roughly 30% of providers have no Health Information ...
(Date:2/21/2017)... ... February 21, 2017 , ... Along with Valentine’s Day, February marks ... small changes that can lead to a lifetime of heart health. In addition, ... emergency. , The Athletic Trainers’ Society of New Jersey (ATSNJ) is urging ...
(Date:2/20/2017)... ... 20, 2017 , ... Daily Body Restore, "DBR" a company ... “good” bacteria in the body, announced its Daily Body Restore® supplement is now ... Body Restore® is made with a unique combination of digestive enzymes and probiotics ...
Breaking Medicine News(10 mins):